BEIJING, April 28, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the registrational Phase III clinical trial of novel BTK inhibitor orelabrutinib for the treatment of systemic lupus erythematosus (SLE). This is a randomized, double-blind, placebo-controlled, multicenter Phase III study evaluating the efficacy and safety of orelabrutinib in patients with SLE, with the SRI-4 response rate at Week 52 as the primary endpoint. The Phase IIb clinical study of orelabrutinib met its primary endpoint, making orelabrutinib the first BTK inhibitor to demonstrate significant efficacy in a Phase II clinical trial for SLE. Under stringent steroid-tapering requirements, orelabrutinib...

Miami, FL, April 28, 2026 (GLOBE NEWSWIRE) — Collective Acquisition Corp. II (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Stock Market LLC (“Nasdaq”) and begin trading tomorrow, April 29, 2026, under the ticker symbol “CAIIU.” Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed...

VANCOUVER, British Columbia, April 28, 2026 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) is pleased to announce that, further to its news release dated February 17, 2026 and February 23, 2026, the Company has closed the second-tranche of a non-brokered private placement of unsecured convertible debentures of the Company (each, a “Debenture”) for a principal amount of $300,000 (the “Offering”). This brings total proceeds raised to date to $600,000. The Debentures will bear interest from their issue date at 8.0% per annum calculated annually & paid on maturity and will mature three (3) years following the date of issuance (the “Maturity Date”). The Debentures are unsecured and will rank pari passu in right of payment of principal and interest...

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. In addition, Oruka has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,449,000 shares of Oruka’s...

Greenville, South Carolina, April 28, 2026 (GLOBE NEWSWIRE) — ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective immediately. The Company wishes Mr. Mirando all the best in his future endeavors.  About ARCpoint Inc.ARCpoint Inc. (TSXV: ARC) operates a technology platform connecting healthcare service providers such as independent collection sites, diagnostic laboratories and telehealth providers into an integrated, direct-to-consumer, cash-based healthcare ecosystem. The platform provides end-to-end technology infrastructure for consumer diagnostic test ordering, specimen collection scheduling, laboratory routing, and electronic result delivery. For more information, please contact: ARCpoint Inc.Adam Ho,...

FORT WORTH, Texas, April 28, 2026 (GLOBE NEWSWIRE) — FirstCash Holdings, Inc. (“FirstCash” or the “Company”) (Nasdaq: FCFS) today announced that the Company’s wholly-owned subsidiary, FirstCash, Inc. (the “Issuer”), has upsized and priced its previously announced private offering of $750,000,000 in aggregate principal amount of senior notes due 2034 (the “Notes”), representing an increase of $150,000,000 in aggregate principal amount from the previously announced proposed offering size. The Notes will pay interest semi-annually at a rate of 6.125% per annum payable on May 1 and November 1 of each year, beginning on November 1, 2026. The Notes will be unsecured senior obligations of the Issuer and will be guaranteed by FirstCash and its domestic subsidiaries that guarantee its revolving unsecured credit facility and existing senior...

Sylogist Board Urges Shareholders to Vote Using Only the BLUE ProxyOneMove is demanding majority Board control — without paying a premium to other shareholders The Board unanimously recommends shareholders vote FOR its six director nominees, plus Board-supported OneMove director nominee Mary Filippelli, vote FOR the Shareholder Rights Plan, and WITHHOLD from OneMove’s three remaining dissident nominees. Shareholders should vote using only the BLUE proxy prior to the deadline of May 8, 2026 at 10:00 AM MT Shareholders who have questions or require assistance voting should contact Laurel Hill Advisory Group Toll-Free by calling 1-877-452-7184 (Canada & USA) or 1-416-304-0211 (international), texting “INFO” to either number, or e-mailing assistance@laurelhill.com For more information and voting instructions, visit...

LONDON, April 28, 2026 (GLOBE NEWSWIRE) — Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that it was notified by the staff of the U.S. Securities and Exchange Commission (the “SEC”) that they have concluded their investigation of the Company relating to Waldencast’s restatement of its financial results and material weaknesses in its internal control over financial reporting related to historical accounting practices used by Obagi Cosmeceuticals (the “Investigation”) and, based on the information available as of the date of the notice, the SEC does not intend to recommend an enforcement action against Waldencast. “We are pleased with the favorable outcome of the SEC’s investigation,” stated Michel Brousset, Chief Executive Officer of Waldencast. “Throughout...

LONG BEACH, Calif. and TORONTO, April 28, 2026 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) today announced that it has delivered a notice of redemption, dated April 28, 2026, with respect to the warrants (the “Warrants”) outstanding under the warrant agency agreement, dated May 13, 2019, between the Company and Odyssey Trust Company, as amended (the “Warrant Agency Agreement”). There are currently 30,664,500 Warrants outstanding, each exercisable for one equity share (each, a “Share”) of the Company at an exercise price of US$11.50 per Share. The outstanding Warrants will be redeemed on May 28, 2026 in accordance with Section 3.4 (1) of the Warrant Agency Agreement at a redemption price of .011826 Shares per...

SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, today announced it has priced a securitization of leases and power purchase agreements. The securitization is Sunrun’s sixteenth securitization since 2015 and first issuance in 2026. “This $584 million securitization transaction further exhibits Sunrun’s ability to access capital at scale and at improving terms,” said Danny Abajian, Sunrun’s Chief Financial Officer. “This securitization was raised with A-1 notes being priced at a 220 basis point credit spread, a 20 basis point improvement from Sunrun’s most recent transactions last year. With the pricing of this securitization, Sunrun has now successfully executed sixteen securitization transactions since 2015, reflecting...